123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan1,000 enrolled

Overview

The aim of this multi-center study is to determine the applicability of BMIPP to diagnosing cardiac disease and to predicting the outcome of patients on hemodialysis.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Coronary Disease Fatty Acids, Unsaturated Radioisotopes Hemodialysis Single Photon Emission Computed Tomography

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria:Adult hemodialysis patients with one or more of the following 10 risk factors for coronary heart disease * Hypertension * Diabetes mellitus * Hyperlipidemia * Obliterative arteriosclerosis in the lower extremities * Smoker * Family history of juvenile coronary artery disease * History of ischemic stroke * History of heart failure requiring hospitalization * Within 3 months after initiation of hemodialysis therapy * Dialysis hypotension Exclusion Criteria:Hemodialysis patients who meet any one of the following conditions will be excluded. * Peritoneal dialysis * Severe valvular disorder requiring treatment * Diagnosis of hypertrophic cardiomyopathy(HCM) or dilated cardiomyopathy(DCM) before start of dialysis * History of revascularization(PCI, CABG) or prior diagnosis of myocardial infarction * Hypersensitivity to BMIPP or its analogue * Judged unsuitable for the study for any other reasons by physicians.

Locations (1)

Toho University Ohashi Medical Center

Meguro-ku, Tokyo, Japan

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.